Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald C Goff

Showing results (1-10 of 207) with videos related to

Pageof 21
Sort By:
JAMA|June 22, 2002
A 23-year-old man with schizophreniaDonald C Goff
Schizophrenia Bulletin|February 28, 2012
D-cycloserine: an evolving role in learning and neuroplasticity in schizophreniaDonald C Goff
JAMA Psychiatry|April 4, 2014
Bitopertin: the good news and bad newsDonald C Goff
The New England Journal of Medicine|April 16, 2020
Promising Evidence of Antipsychotic Efficacy without Dopamine D2-Receptor BindingDonald C Goff
Current Opinion in Psychiatry|February 25, 2015
Drug development in schizophrenia: are glutamatergic targets still worth aiming at?Donald C Goff
The American Journal of Psychiatry|August 5, 2008
New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients' quality of lifeDonald C Goff
The American Journal of Psychiatry|March 1, 2026
With No Surprises From the EMERGENT-4 Trial, Where Do We Go From Here?Donald C Goff
Journal of Clinical Psychopharmacology|February 6, 2025
At Last, a Nondopaminergic Agent for the Treatment of Schizophrenia: The Combination of Xanomeline and Trospium (Cobenfy)Donald C Goff
The American Journal of Psychiatry|September 2, 2015
Brexpiprazole: A New Antipsychotic Following in the Footsteps of AripiprazoleDonald C Goff
The American Journal of Psychiatry|February 2, 2018
Optimizing the Pharmacologic Treatment of Individuals With First-Episode PsychosisDonald C Goff
Pageof 21

Showing results (1-10 of 207) with videos related to

Sort By:
Pageof 21
JAMA|June 22, 2002
A 23-year-old man with schizophreniaDonald C Goff
Schizophrenia Bulletin|February 28, 2012
D-cycloserine: an evolving role in learning and neuroplasticity in schizophreniaDonald C Goff
JAMA Psychiatry|April 4, 2014
Bitopertin: the good news and bad newsDonald C Goff
The New England Journal of Medicine|April 16, 2020
Promising Evidence of Antipsychotic Efficacy without Dopamine D2-Receptor BindingDonald C Goff
Current Opinion in Psychiatry|February 25, 2015
Drug development in schizophrenia: are glutamatergic targets still worth aiming at?Donald C Goff
The American Journal of Psychiatry|August 5, 2008
New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients' quality of lifeDonald C Goff
The American Journal of Psychiatry|March 1, 2026
With No Surprises From the EMERGENT-4 Trial, Where Do We Go From Here?Donald C Goff
Journal of Clinical Psychopharmacology|February 6, 2025
At Last, a Nondopaminergic Agent for the Treatment of Schizophrenia: The Combination of Xanomeline and Trospium (Cobenfy)Donald C Goff
The American Journal of Psychiatry|September 2, 2015
Brexpiprazole: A New Antipsychotic Following in the Footsteps of AripiprazoleDonald C Goff
The American Journal of Psychiatry|February 2, 2018
Optimizing the Pharmacologic Treatment of Individuals With First-Episode PsychosisDonald C Goff
Pageof 21